Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases
NCT ID: NCT06405256
Last Updated: 2024-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20 participants
OBSERVATIONAL
2020-01-03
2025-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurococognitive and Functioal Assessment of Patients With Brain Metastases
NCT01861405
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
NCT04805255
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
NCT02031237
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
NCT06201351
Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer
NCT03002532
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BM patients receiving MRIgART
For it's an observational study, all patients eligible will be divided into the group "BM patients receiving MRIgART"
magnetic resonance imaging-guided adaptive radiotherapy
Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
magnetic resonance imaging-guided adaptive radiotherapy
Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. pathologically confirmed lung cancer.
3. diagnosed with brain metastases by enhanced MRI.
4. BM volume ≥ 2cm.
5. Anticipated time to survival\>3 months.
6. Treated with Unity MR-linac.
7. Good compliance; Able to stay still in supine position for 45 minutes and above.
Exclusion Criteria
2. Suffer from severe back pain in supine position, unable to receive Unity MR-linac.
3. Suffer from severe claustrophobia.
4. Incomplete pre-Unity image data.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nan Bi, MD
Role: PRINCIPAL_INVESTIGATOR
Chinese Academy of Medical Sciences and Peking Union Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese Academy of Medical Science and Peking Union Medical College
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMMRIgART
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.